Search results for: Multi-Indication Medicines
Filter search results
Workshop on HTA and Regulatory Review
13 May 2010
…occur between health technology assessment (HTA) and regulatory approval of medicines. In autumn 2009, OHE and the Institute for Regulatory Science at CMR International collaborated on a two-day workshop on…
Access to Orphan Drugs in the EU
21 October 2010
…lower risk-benefit ratios for OMPs than for other new medicines. When a formal health technology assessment (HTA) process is required, however, evidence requirements are the same as for non-OMP drugs (except…
The UK’s Publicly Funded Vaccines Market
23 November 2010
…and specialised JCVI as the evaluator, rather than NICE, both because of the difference between vaccines and curative prescription medicines and because of the deep expertise of the JCVI membership….
New OHE Report: Time Trends in NICE HTA Decisions
25 January 2012
…innovative care and ensure more rapid access to medicines identified as being of value to the NHS. Since NICE’s debut in April 1999, several analyses have examined the uptake of…
Spotlight on OHE: Valuing Spillovers, End-of-Life Decisions and Hospital Outcomes
20 March 2012
…in all three of its main areas of research. The economic benefits of research on medicines, inside and outside the pharmaceutical industry, extend far beyond the development of important new…
New Research on VBP: Disease Severity and Unmet Need in the UK
24 April 2012
The UK Department of Health’s value based pricing (VBP) Consultation Document proposes a process whereby higher prices would be granted to medicines that tackle diseases that produce the greatest burdens…
New OHE Consulting Report Explores the Many Faces of Innovation
19 June 2012
Now available from the OHE website, this report provides a clear explanation of the complex nature of innovation in medicines. A fully revised and expanded version of the 2005 edition…
Save the Date: Drug Development in 2022, OHE’s 50th Anniversary Conference
21 June 2012
…include: Dr Richard Barker, Director of the Centre for Accelerating Medical Innovations, University of Oxford Professor Sir Alasdair Breckenridge, Chairman of the UK Medicines and Healthcare products Regulatory Agency (MHRA)…
Register Now for the OHE Conference on Drug Development in 2022
2 July 2012
…Sir Alasdair Breckenridge, Chairman of the UK Medicines and Healthcare products Regulatory Agency (MHRA) Professor Patricia Danzon, The Wharton School, University of Pennsylvania Dr Hans-Georg Eichler, Senior Medical Officer, European…